Tau PET imaging: present and future directions

• Published in: Molecular neurodegeneration Vol. 12; no. 1; p. 19
• Main Authors: Saint-Aubert, Laure, Lemoine, Laetitia, Chiotis, Konstantinos, Leuzy, Antoine, Rodriguez-Vieitez, Elena, Nordberg, Agneta
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 20.02.2017; BioMed Central
• Subjects: Alzheimer Disease - diagnosis; Alzheimer Disease - metabolism; Alzheimer's disease; Animals; Carbolines - pharmacology; Care and treatment; Cerebrospinal fluid; Diagnosis; Humans; PET imaging; Physiological aspects; Positron-Emission Tomography - methods; Radioactive Tracers; Review; Tau proteins; tau Proteins - metabolism; Tauopathies - metabolism; Tracer development; Clinical research; Tau; Biomarker; Neurodegenerative diseases; Positron emission tomography imaging
• DOI: 10.1186/s13024-017-0162-3
• ISSN: 1750-1326

Abnormal aggregation of tau in the brain is a major contributing factor in various neurodegenerative diseases. The role of tau phosphorylation in the pathophysiology of tauopathies remains unclear. Consequently, it is important to be able to accurately and specifically target tau deposits in vivo in the brains of patients. The advances of molecular imaging in the recent years have now led to the recent development of promising tau-specific tracers for positron emission tomography (PET), such as THK5317, THK5351, AV-1451, and PBB3. These tracers are now available for clinical assessment in patients with various tauopathies, including Alzheimer's disease, as well as in healthy subjects. Exploring the patterns of tau deposition in vivo for different pathologies will allow discrimination between neurodegenerative diseases, including different tauopathies, and monitoring of disease progression. The variety and complexity of the different types of tau deposits in the different diseases, however, has resulted in quite a challenge for the development of tau PET tracers. Extensive work remains in order to fully characterize the binding properties of the tau PET tracers, and to assess their usefulness as an early biomarker of the underlying pathology. In this review, we summarize recent findings on the most promising tau PET tracers to date, discuss what has been learnt from these findings, and offer some suggestions for the next steps that need to be achieved in a near future.